Chemman Labs Private Limited

Based in Madhya Pradesh, India, and founded in 2020, Chemman Labs Private Limited specializes in pharmaceutical product development and manufacturing, particularly in sterile injectables. In February 2024, Eris Lifesciences Limited, a portfolio company of ChrysCapital and Kuwait Investment Authority, agreed to fully acquire Chemman Labs Private Limited. Chemman Labs Private Limited’s core offerings include biological products, biosimilars, and vaccines, with an emphasis on complex biologics for various therapeutic applications. The company employs advanced manufacturing technologies, such as Fundamix, for drug product filling, ensuring that they cater to a diverse range of medical needs.

Chemman's client base consists of hospitals, healthcare providers, and pharmaceutical distributors, primarily serving regulated markets in North America, Europe, and emerging markets across Asia and Africa. Chemman Labs generates revenue through direct sales and partnerships with healthcare providers, pharmaceutical distributors, and wholesalers. Transactions typically occur in a B2B model, where healthcare facilities procure their injectable products to meet patient demands. The company is strategizing to introduce new pharmaceutical products and enhance its market presence in specific regions, with plans to enter additional markets across Asia and Europe by the end of 2025.